Economic Evaluation of First Line Treatment for Advanced Non Small Cell Lung Cancer Using Tyrosine Kinase Inhibitors in Malaysia

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.08.280
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared With Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer

PLoS ONE
Multidisciplinary
2014English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients With Advanced Non-Small Cell Lung Cancer

Current Gerontology and Geriatrics Research
GerontologyGeriatrics
2010English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors

2013English

Analysis of Continuous First‑line Treatment With Docetaxel and Carboplatin for Advanced Non‑small Cell Lung Cancer

Oncology Letters
Cancer ResearchOncology
2014English

Overcoming Resistance to First/Second Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and ALK Inhibitors in Oncogene-Addicted Advanced Non-Small Cell Lung Cancer

Therapeutic Advances in Medical Oncology
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy